• 1
    Simons FER. Allergic Rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1994;104: 534540.
  • 2
    Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic implications. Thorax 2000;55: s26s27.
  • 3
    Annaesi-Maesano I. Epidemiological evidence of the occurrence of rhinitis and sinusitis in asthma. Allergy 1999;54: 713.
  • 4
    . The International Study of Asthma and Allergies in Childhood (ISAAC). Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema. Lancet 1998;351: 12251232.
  • 5
    Gergen PJ, Turkeltaub PC. The association of individual allergen reactivity with respiratory disease in a national sample. Data from the second National Health and Nutrition Examination Survey 1976–80 (NHANES), J Allergy Clin Immunol 1992;90: 579588.
  • 6
    Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol 1998;101: s352s356.
  • 7
    Ciprandi G, Vizzaccaro A, Cirillo I et al. Increase of asthma and allergic rhinitis in Italian young men. Int Arch Allergy Immunol 1996;111: 278283.
  • 8
    Kapsali T, Horowitz E, Togias A. Rhinitis is ubiquitous in allergic asthmatics. J Allergy Clin Immunol 1999;99: S138.
  • 9
    Leynaert B, Neukirch F, Demoly P, Bouequet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000;106: S201S205.
  • 10
    Settipane G, Settipane RJ, Hagy GW. Long term risk factors for developing asthma amd allergic rhinitis: a 23 year follow up study of college students. Allergy Proc 1994;15: 2125.
  • 11
    Anderson HR, Pottier AC, Strachan DP. Asthma from birth to age 23: incidence and relationship to prior and concurrent atopic status. Thorax 1992;47: 537542.
  • 12
    Jenkins MA, Hopper JL, Flander LB et al. The associations between childhood asthma, and atopy, and parental asthma, hay fever and smoking. Paediatr Perinat Epidemiol 1993;7: 6776.
  • 13
    Lombardi C, Passalacqua G, Gargioni S et al. The natural history of respiratory allergy: a follow up study of 99 patients up to 10 years. Respir Medical 2001 (in press).
  • 14
    Braman SS, Barrows AA, Decotiis BA et al. Airways hyperresponsiveness in allergic rhinitis. A risk factor for asthma. Chest 1987;91: 671674.
  • 15
    Amsdale EH, Morris MM, Roberts RS, Hargreave FE. Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol 1985;75: 573577.
  • 16
    Littell NT, Carlisle CC, Millman RP, Brannan SS. Changes in airways resistance following nasal provocation. Am Rev Respir Dis 1990;141: 580583.
  • 17
    Corren J, Adinoff A, Irvin C. Changes in bronchial responsiveness following nasal provocation with allergens. J Allergy Clin Immunol 1992;89: 611618.
  • 18
    Braunstahl GJ, Overbeek SE, Kleinjan A et al. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001;107: 469476.
  • 19
    Braunstahl G, Kleinjan A, Overbeek SE et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000;161: 20512057.
  • 20
    Kay AB. Allergy and allergic diseases. First of two parts. New Eng J Med 2001;344: 3037.
  • 21
    Ciprandi G, Pronzato C, Ricca V et al.. Specific allergen challenge induces ICAM-1 expression on nasal epet al.ithelial cells in allergic subjects. Am Rev Respir Crit Care Med 1994;150: 16531659.
  • 22
    Polosa R, Ciamarra I, Mangano G et al. Bronchial hyperresponsiveness and airway inflammation markers in nonasthmatics with allergic rhinitis. Eur Resp J 2000;15: 3035.
  • 23
    Crimi E, Milanese M, Oddera S et al. Inflammatory and mechanical factors of allergen-induced bronchoconstriction in mild asthma and rhinitis. J Appl Physiol 2001;91: 10291034.
  • 24
    Denburgh J. The nose, the lung and the bone marrow in allergic inflammation. Allergy 1999;54: 7380.
  • 25
    Gaspar Elsas MI, Joseph D, Elsas P, Vargaftig BB. Rapid increase in bone marrow eosinophil production and responses to eosinopoietic interleukin triggered by intranasal allergen challenge. Am J Respir Cell Mol Biol 1997;17: 404413.
  • 26
    Togias A. Unique mechanistic features of allergic rhinitis. J Allegy Clin Immunol 2000;105: S599S604.
  • 27
    Leynaert B, Bousquet J, Neukirch C et al. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects. J Allergy Clin Immunol 1999;104: 301304.
  • 28
    Undem BJ, McAlexander M, Hunter DD. Neurobiology of the upper and lower airways. Allergy 1999;54: 8193.
  • 29
    McLane ML, Nelson JA, Lenner KA et al. Integrated response of the upper and lower respiratory tract of asthmatic subjects to frigid air. J Appl Physiol 2000;88: 10431050.
  • 30
    Fontanari P, Burnet H, Zattera-Hartmann C, Jammes Y. Changes in airways resistance induced by nasal inhalation of cold dry, dry or moist air in normal individuals. J Appl Physiol 1996;81: 17391743.
  • 31
    Blumenthal MN. Genetics of asthma and allergy. Allergy Asthma Proc 2000;21: 5559.
  • 32
    Johansson SGO, O' B, Hourihane J, Bousquet J et al. Position Paper. A revised nomenclature for allergy. EAACI Position Statement Allergy 2001;56: 813824.
  • 33
    Shirakawa T, Enomoto T. The inverse association between tuberculin response and atopic disorders. Science 1997;275: 7779.
  • 34
    Von Mutius E. The environmental predictors of allergic disease. J Allergy Clin Immunol 2000;105: 919.
  • 35
    Weiland SK, Von Mutius E, Hirsch T et al. Prevalence of respiratory and atopic disorders among chilgren in the east and west Germany after unification. Eur Resp J 1999;14: 862970.
  • 36
    Bjorksten B. Environment and infant immunity. Proc Nutr Soc 1999;58: 729732.
  • 37
    Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease. A placebo controlled trial. Lancet 2001;357: 10761079.
  • 38
    Romagnani S. The Th1/Th2 paradigm and allergic disorders. Allergy 1998;53: 1215.
  • 39
    Kon OM, Kay AB. T cells and chronic asthma. Int Arch Allergy Immunol 1999;118: 133135.
  • 40
    Galli G, Annunziato M, Mavilia F et al. Ehanced HIV expression during Th2 oriented response explained by the opposite regulatory effect of IL-4 and IFNgamma of fusin CXCR4. Eur J Immunol 1998;28: 32803290.
  • 41
    Kawano Y, Noma T. Dual action of IL-4 on mite antigen induced IgE synthesis in lymphocytes from individuals with bronchial asthma. Clin Exp Immunol 1995;102: 389394.
  • 42
    Ohnishi T, Kita H, Weiler D et al. IL-5 is the predominant eosinophil-active cytokine in the antigen induced pulmonary late phase reaction. Am Rev Respir Dis 1993;147: 901907.
  • 43
    Lalani T, Simmons RK, Ahmed AR. Biology of IL-5 in health and disease. Ann Allergy Asthma Immunol 1999;82: 317332.
  • 44
    Cieslewicz G, Tomkinson A, Adler A et al. The late but not early asthmatic response is dependent on or correlates with eosinophil infiltration. J Clin Invest 1999;104: 301308.
  • 45
    Doucet C, Brouty-Buye D, Poitin-Clemenceau C et al. IL-4 and IL-13 specifically increase adhesion molecule expression in human lung fibroblast. Int J Immunol 1998;10: 14211433.
  • 46
    Smith CH, Barker JW, Lee TH. Adhesion molecules in allergic inflammation. Am Rev Resp Dis 1993;148: s175.
  • 47
    Vignola AM, Campbell A, Chanez P et al. HLA DR and ICAM 1 expression in asthma and chronic bronchitis. Am Rev Resp Dis 1993;148: 689694.
  • 48
    Jeffery PK, Wardlaw AJ, Nelson FC et al. Bronchial biopsies in asthma. An ultrastructural quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989;140: 17451753.
  • 49
    Ciprandi G, Buscaglia S, Pesce GP et al. Minimal persistent inflammation is present at mucosal level in asymptomatic rhinitic patients with allergy due to mites. J Allergy Clin Immunol 1995;96: 971979.
  • 50
    Ricca V, Landi M, Ferrero E, Canonica GW, Ciprandi G. Minimal persistent inflammation is also present in patients with pollen allergy. J Allergy Clin Immunol 2000;105: 5463.
  • 51
    Greve JM, Davis G, Meyer AM et al. The major human rhinovirus receptor is ICAM-1. Cell 1989;56: 839.
  • 52
    Johnston SL, Pattermore PK, Sanderson G et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996;154: 654660.
  • 53
    Johnston SL, Pattermore PK, Sanderson G et al. A longitudinal study on the role of viral infections in exacerbations of asthma in school children in the community. BMJ 1995;310: 12251229.
  • 54
    Durham SR. Effect of intranasal corticosteroid treatment on asthma in children and adults. Allergy 1999;54: 124131.
  • 55
    Corren J, Adinoff AD, Buckmeier AD, Irwin CG. Nasal beclometasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992;90: 250256.
  • 56
    Foresi A, Pelucchi A, Gherson G et al. Once daily intranasal fluticasone propionate (200 micrograms) reduce nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996;98: 274282.
  • 57
    Watson WT, Becker AB, Simons FER. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol 1993;91: 97101.
  • 58
    Aubier M, Levy J, Clerici C, Neukirch F et al. Different effects of nasal and bronchial glucocorticosteroids administration on bronchial responsiveness in patients with rhinitis. Am Rev Respir Dis 1992;146: 122126.
  • 59
    Gani F, Crivellaro MA, Landi M et al. The role of patient training in the management of allergic rhinitis and asthma: clinical implications. Allergy 2001;56: 6568.
  • 60
    Ciprandi G, Passalacqua G, Canonica GW. Effect of H1 antihistamines on adhesion molecules: a possible rationale for long term treatment. Clin Exp Allergy 1999;29: 4952.
  • 61
    Grant JA, Nicodemus CF, Findlay SR at al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized controlled trial. J Allergy Clin Immunol 1995;95: 923932.
  • 62
    Corren J, Harris AG, Aaronson D et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and asthma. J Allergy Clin Immunol 1997;100: 781788.
  • 63
    Aubier M, Neukirch C, Peiffer C, Melac M. Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma. Allergy 2001;56: 3542.
  • 64
    Roquet A, Dahlen B, Kumlin M et al. Combined antagonism of leukotriene and histamine produces a predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997;155: 18561863.
  • 65
    Meltzer EO, Malmstrom K, Lu S et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo controlled clinical trial. J Allergy Clin Immunol 2000;105: 917922.
  • 66
    Ciprandi G, Ricca V, Tosca MA et al. Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy 1999;54: 358365.
  • 67
    Ciprandi G, Tosca MA, Passalacqua G, Canonica GW. Longterm cetirizine treatment reduces allergic symptoms and supplemental medication use in children with mite allergy. Ann Allergy Asthma Immunol 2001;87: 222226.
  • 68
    The ETAC, Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double blind randomized placebo controlled trial. Pediatr Allergy 1998;3: 116124.
  • 69
    Oliveira CA, Solé D, Naspitz CK et al. Improvement of bronchial hyperresponsiveness in asthmatic children treated for concomitant sinusitis. Ann Allergy Asthma Immunol 1997;79: 7074.
  • 70
    Goldstein MF, Grundfast SK, Dunsky EH et al. Effect of functional endoscopic sinus surgery on bronchial asthma outcomes. Arch Otolaryngol Head Neck Surg 1999;125: 314319.
  • 71
    Ikeda K, Tanno N, Tamura G et al. Endoscopic sinus surgery improves pulmonary function in patients with asthma associated with chronic sinusitis. Ann Otol Rhinol Laryngol 1999;108: 355359.
  • 72
    Durham SR, Till J. Immunological changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102: 157164.
  • 73
    Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen induced late skin response after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99: 254260.
  • 74
    Durham SR, Ying S, Varney VA et al. Grass pollen immunotherapy inhibits allergen induced infiltration of CD T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon gamma. J Allergy Clin Immunol 1996;97: 13561365.
  • 75
    Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass pollen immunotherapy. N Eng J Med 1999;341: 468475.
  • 76
    Hedlin G, Heilborn H, Liljia G et al. Long term follow up of patients treated with a three-year couse of cat or dog immunotherapy. J Allergy Clin Immunol 1995;96: 879885.
  • 77
    Ariano R, Kroon AM, Augeri G, Canonica GW, Passalacqua G. Long term treatment with allergoid immunotherapy with parietaria. Clinical and immunological effects in a randomized, controlled trial. Allergy 1999;54: 135138.
  • 78
    Des-Roches A, Paradis L, Knani J et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V – Duration of efficacy of immunotherapy after its cessation. Allergy 1996;51: 430434.
  • 79
    Pajno GB, Barberio G, De Luca E, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31: 1392–1397.
  • 80
    Holt PG, Sly PD. Allergic respiratory disease: strategic targets for primary prevention during childhood. Thorax 1997;52: 14.
  • 81
    Malling HJ, Abreu-Noguera E, Alvarez-Cuesta E et al. EAACI/ESPACI Position paper on local immunotherapy. Allergy 1998;55: 833844.
  • 82
    Bousquet J, Kalthaev N and Van Cauwenberge P, edts. WHO Position Paper. ARIA. Allergic Rhinitis and its Impact on Asthma. World Health Organization JACI, 2001 (in press).
  • 83
    Giannarini L, Maggi E. Decrease of allergen specific T cell response induced by local nasal immunotherapy. Clin Exp Allergy 1998;28: 404412.
  • 84
    Fanta C, Bohle H, Hirt W et al. Systemic immunological changes induced by administration of grass pollen allergen via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 1999;120: 218224.
  • 85
    Passalacqua G, Albano M, Fregonese L, Riccio Am Pronzato C, Mela GS, Canonica GW. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite induced rhinoconjunctivitis. Lancet 1998;351: 629632.
  • 86
    Passalacqua G, Albano M, Riccio AM et al. Clinical and immunological effect of a rush sublingual immunotherapy to parietaria species: a double blind placebo controlled trial. J Allergy Clin Immunol 1999;104: 964968.
  • 87
    Andre C, Carat F. Safety of sublingual immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121: 229234.
  • 88
    Di Rienzo V, Parmiani S, Passalacqua G, Canonica GW. Post marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999;54: 125.
  • 89
    Fahy VJ. Reducing IgE levels as a strategy for treatment of asthma. Clin Chest Med 2000;21: 263277.
  • 90
    Milgrom HG, Fick RB, Su JQ et al. Treatment of allergic asthma with monoclonal anti IgE antibody. RhuMAb E25 study group. N Eng J Med 1999;341: 19661973.
  • 91
    Adrlroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106: 253259.
  • 92
    Casale TB, Bernstein IL, Busse VW et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100: 110121.
  • 93
    Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes N. Randomised dose-ranging placebo controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998;352: 11091113.
  • 94
    Sani Y, Myamoto T, Makino S. Antiinflammatory effect of suplatast tosilate in mild asthma. Chest 1997;112: 862863.
  • 95
    Tamaoki J, Kondo M, Sakai N et al. Effect of suplatast tosilate a Th2 cytokine inhibitor on steroid dependent asthma: a double blind randomised study. Lancet 2000;56: 14211422.
  • 96
    Wills-Karp M, Gavett SH, Schofiels B, Finkelman F. Role of interleukin 4 in the development of allergic airway inflammation and airways hyperresponsiveness. Adv Exp Med Biol 1996;409: 343347.
  • 97
    Hogan P, Foster PS. Cytokines as targets for the inhibition of eosinophilic inflammation. Pharmacol Ther 1997;74: 259283.
  • 98
    Zhang X, Polla B, Hauser C, Zubler RH. T cells from atopic individuals produce IgE inducing activity which is incompletely blocked by anti IL-4 antibody. Eur J Immunol 1992;22: 829833.
  • 99
    Van der Pouw Kraan CT, Aalberse RC, Aarden LA. IgE production in atopic patients is not related to Il−4 production. Clin Exp Immunol 1994;97: 254259.
  • 100
    Borish LC, Nelson HS, Lanz MJ et al. IL-4 receptor in moderate atopic asthma. A phase I/II randomized placebo controled trial. Am J Respir Crit Care Med 1999;160: 18161823.
  • 101
    Garlisi GC. IL-5 inhibition as a therapy for allergic diseases. Pulm Pharmacol Ther 1999;12: 8185.
  • 102
    Dickason RR, Huston MM, Huston P. Delineation of IL-5 domains predicted to engage the IL-5 receptor. J Immunol 1996;156: 10301037.
  • 103
    Danzig M, Cuss F. Inhibition of interleukin 5 with a monoclonal antibody attenuates allergic inflammation. Allergy 1997;52: 787794.
  • 104
    Egan RW, Athwal D, Bodmer MW et al. Effect of SCH55700, a humanized antibody to human IL-5, on eosinophilic response ad bronchial hyperreactivity. Arzneimittelforschung 1999;49: 779790.
  • 105
    Mauser P, Pitman AM, Fernandez X et al. Effects of an antibody to IL-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995;152: 467469.
  • 106
    Leckie MJ, Ten Brinke A, Khan J et al. Effects of an Interleukin 5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000;356: 21142116.
  • 107
    Bryan SA, O'Connor BJ, Matti S et al. Effect on recombinant human IL-12 on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000;356: 21142116.
  • 108
    Aubier M. Linking upper and lower respiratory airways. J Allergy Clin Immunol 1999;83: 431434.
  • 109
    Passalacqua G, Ciprandi G, Canonica GW. The nose–lung interaction: united airways disease. Curr Opin Allergy Clin Immunol 2001;1: 714.